Corporate
Factor Bioscience Takes Control of Tempest Therapeutics, Installs CEO Matt Angel After 74% Stock Collapse
9h ago
You're signed outSign in or to get full access.
TT
Tempest Therapeutics (TPST)·Earnings Reports
Q4 2024
View earnings summary and analysis
Q3 2024
View earnings summary and analysis
Q2 2024
View earnings summary and analysis
Q1 2024
View earnings summary and analysis
Research analysts covering Tempest Therapeutics.